Picture loading failed.

Anti-LILRA4 therapeutic antibody (Pre-made Daxdilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19. and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-135-1mg 1mg 3090
GMP-Bios-ab-135-10mg 10mg 21890
GMP-Bios-ab-135-100mg 100mg 148000
GMP-Bios-ab-135-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-LILRA4 therapeutic antibody (Pre-made Daxdilimab biosimilar,Whole mAb)
INN Name Daxdilimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesViela Bio
Conditions Approvedna
Conditions ActiveCutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury
Conditions Discontinuedna
Development Techna